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ABSTRACT
Four experiments were conducted in an effort to develop a method, based on prolactin
secretion, for assessing the efficacy and duration of activity of dopaminergic agonists for the
treatment of pituitary pars intermedia dysfunction (PPID) in horses. In the first experiment,
prolactin response to a low dose of the dopamine antagonist, sulpiride, was generally repeatable
in estrogen-primed geldings in winter over 8 every-other-day challenges. It was concluded that
estrogen-primed, sulpiride-challenged geldings in winter could serve as a model for the study of
potential dopaminergic drugs for the treatment of PPID in horses. The second experiment was
performed in the summer with mares, and again tested the repeatability of the prolactin responses
over a 30-day period. The responses in mares were generally repeatable, and there was no effect
due to stage of the estrous cycle. It was concluded that mares could serve as a model for the
study of potential dopaminergic drugs as well as geldings, and stage of the estrous cycle did not
have to be taken into account. In the third experiment, two formulations of the dopamine agonist,
pergolide, were tested (oral administration versus injection) against a single formulation of
cabergoline (injected) and control injections (vehicle) for their efficacy to reduce unstimulated
plasma prolactin concentrations in geldings. Oral pergolide reduced prolactin concentrations for
a few hours, whereas injected pergolide suppressed prolactin concentrations for 24 hours.
Cabergoline suppressed prolactin concentrations for up to 5.5 days. It was concluded that the
injectable formulations had potential for further study as possible treatments for PPID in horses.
The last experiment tested the efficacy of daily pergolide injection versus a single injection of
cabergoline, for suppressing the prolactin secretion induced by low dose sulpiride injections in
mares. Daily injection of pergolide suppressed prolactin responses as long as the injections were
given, plus another 2 days. The single cabergoline injection suppressed prolactin responses for a
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minimum of 10 days. Based on these results, cabergoline in slow-release vehicle seems to
provide an excellent possibility for administering dopaminergic activity to horses with PPID.
Whether these results are directly applicable to PPID horses needs to be determined.
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INTRODUCTION
Pituitary pars intermedia dysfunction (PPID), also referred to as equine Cushing's
disease, is a common disease in older horses caused by an abnormal stimulation of the adrenal
glands by products from the cells of the intermediate lobe of the pituitary gland (McFarlane,
2011). The hypersecretion of cortisol from the adrenal cortex results in several undesirable
symptoms, including constantly long, curly hair coat (hirsuitism), insulin resistance, excessive
drinking and urination (polyuria and polydipsia), laminitis, lethargy, excessive sweating, loss of
muscle mass, repeated infections such as sole abscesses, tooth root infections, and sinusitis, as
well as infertility (Messer, 1999). The presence and severity of symptoms generally depends
upon the length of time the disease goes untreated (McFarlane, 2011).
The cells of the intermediate lobe that are purported to be responsible for the disease are
the melanotropes, cells that normally produce and secrete α-melanocyte stimulating hormone (αMSH, hereafter referred to as MSH), which is involved with skin and hair coloring in most
species (Hadley and Levine, 2007). The activity of the melanotropes is known in other species to
be regulated by the hypothalamic secretion of dopamine, an inhibitory neurotransmitter that
keeps MSH secretion within normal limits (Hadley and Levine, 2007). Prolactin, a hormone
produced by the lactotropes of the adenohypophysis, is regulated by the hypothalamus in the
same manner, i.e., by dopamine, and its secretion is constantly under negative feedback (Moore,
1987; Saiardi and Borrelli, 1998). The nature of this negative tone is revealed when horses are
administered a dopamine receptor antagonist, such as domperidone or sulpiride; plasma
concentrations of both hormones (MSH and prolactin) increase within minutes (Johnson and
Becker, 1987; Brendemuehl and Cross, 2000; Beech et al., 2011).
The current understanding of the cause of PPID involves a reduced dopamine secretion
from the hypothalamus in older horses (McFarlane et al., 2005), thereby increasing the activity
1

of the melanotropes and perhaps shifting their production from MSH to adrenocorticotropic
hormone (ACTH; Saiardi and Borrelli, 1998). The currently accepted treatment for PPID
therefore is based on drugs that mimic the activity of dopamine, thereby suppressing the activity
of the melanotropes. Pergolide, a drug previously used in human medicine for treatment of
Parkinson's disease, is now approved for use in horses to treat PPID (Schott, 2002). Cabergoline,
another dopamine agonist, has been suggested as a longer acting, and perhaps less expensive,
alternative to pergolide in humans (Godbout et al., 2010), and may be applicable to PPID horses.
The experiments described herein were conducted in an effort to devise a model, using
prolactin secretion, to study the efficacy and duration of action of dopaminergic drugs for the
treatment of PPID. Even though pergolide is currently sold for the treatment of PPID, it is
expensive, needs to be administered daily, and is likely of lower activity as a dopamine agonist
relative to cabergoline. The rationale for using prolactin, rather than MSH or ACTH, as the
monitor of the effects of the drugs being tested is primarily cost. Commercial kits for ACTH and
MSH are expensive, and their measurement requires the use of aprotinin as an inhibitor of
protease activity in the blood samples collected. Prolactin measurement in the LSU Agricultural
Center School of Animal Sciences is more cost effective compared to the costs of the
commercial kits.

2

CHAPTER 1
REVIEW OF LITERATURE
Prolactin
In 1928, Stricker and Grueter reported that milk secretion could be stimulated in rabbits
by giving them extract of the anterior pituitary gland (cited by Hadley and Levine, 2007).
However, upon injecting the extract directly into the mammary ducts, only the alveoli attached to
those treated ducts produced milk. This result indicated that more hormones acted jointly with
prolactin in controlling mammary gland development (Hadley and Levine, 2007). Prolactin was
the name Riddle, Bates, and Dykshorn had given to a fraction of bovine pituitary extracts that
had stimulated crop sac growth in pigeons (cited by Hadley and Levine, 2007). The majority of
prolactin production and secretion occurs in the adenohypophysis by the cells referred to as
lactotropes, but it can also be produced from the mammary glands, uterus, placenta, and Tlymphocytes (Bachelot and Binart, 2007). Prolactin’s structure, in most mammals, consists of
between 197 and 199 amino acids in one single chain (Sinha, 1995). Most often regarded as the
lactogenesis and mammary growth and development hormone, prolactin actually plays a very
diverse role in reproduction in both males and females, giving it the title of the “hormone of
maternity” (Hadley and Levine, 2007).
Control of Prolactin Secretion
Prolactin secretion, unlike that of most other adenohypophyseal hormones, increases after
removal of hypothalamic input to the pituitary gland (e.g., in dispersed cell suspensions, or after
transection of the stalk-median eminence; Hadley and Levine, 2007). This led to the discovery
that the neurotransmitter found throughout the brain and peripheral structures in the body,
dopamine, was the main, if not sole, source of the tonic inhibition of prolactin secretion in most
mammals (Ben-Jonathan, 1985). Dopamine is released into the hypophysial portal system
3

through the tuberoinfundibular neurons located in the mediobasal hypothalamus (Moore, 1987).
These dopaminergic neurons are unique from the others of their kind; they are not directly
regulated by dopaminergic receptor-mediated mechanisms, but by concentrations of prolactin in
blood and cerebrospinal fluid (Moore, 1987). After dopamine has been released into the portal
system, it attaches to type-2 dopamine (D2) receptors that are linked to membrane channels, as
well as G proteins, and suppresses the secretory activities of the lactotropes (Ben-Jonathan and
Hnasko, 2001). Not only does dopamine inhibit prolactin secretion through control of calcium
fluxes in this manner, it also activates intracellular signaling pathways and represses prolactin
gene expression and the proliferation of lactotropes (Ben-Jonathan and Hnasko, 2001).
Prolactin Secretion and Actions in Horses
Most research in horses has dealt with factors that affect prolactin secretion, including
season (Johnson, 1986; Thompson et al., 1986a), meal consumption (Nadal, et al., 1997;
McManus and Fitzgerald, 2000), exercise or stress (Colborn et al., 1991; Thompson et al., 1994),
endophyte-infected tall fescue consumption (McCann et al., 1992), sex and gonadal presence
(Thompson et al., 1986a), treatment with dopaminergic antagonists (Donadeau and Thompson,
2002; Thompson and DePew, 1997) or thyrotropin releasing hormone (TRH; Johnson, 1986;
Thompson et al., 1986b), and estradiol pretreatment (Kelley et al., 2006). Plasma prolactin
concentrations in horses, like in most mammals, are stimulated by the long days of summer, and
are lowest during the short days of winter (Nequin et al., 1993). Most physical stimuli, such as
exercise or other forms of stress, and administration of sulpiride, domperidone (dopamine
receptor antagonists), or TRH all cause increases in prolactin secretion within a matter of
minutes. Geldings have significantly lower plasma prolactin concentrations in spring than mares
or stallions, which have similar concentrations, however the response to exercise is similar in all
three types of horses (Thompson et al., 1994).
4

Apparently the increasing prolactin concentrations in the spring are involved with loss of
the winter hair coat (Thompson et al., 1997) as well as the return of ovarian activity in mares
(Nequin et al., 1993). Treatment of seasonally anovulatory mares with prolactin stimulated
ovarian activity (Nequin et al., 1993) and induced ovulation (Thompson et al., 1997); subsequent
production of anti-prolactin antibodies, which would neutralize the mares' endogenous prolactin,
resulted in failure to shed the winter coat well into the spring (Thompson et al., 1997).
Strong evidence for the need for prolactin in mares for mammary development and
subsequent milk production is derived from the research on fescue toxicity in mares (Redmond et
al., 1994). Consumption of endophyte-infected tall fescue in the last 3 months of pregnancy is
associated with greatly reduced plasma prolactin concentrations and a failure of udder
development in mares (Cross et al., 1995), and treatment with a dopamine antagonist
(domperidone) has been shown to reverse those effects (Cross et al., 1995).
Adrenocorticotropic Hormone
Adrenocorticotropic hormone, also referred to as corticotrophin, is produced in the
basophils of the pars distalis of the adenohypophysis, and is the smallest adenohypophyseal
hormone, consisting of only 39 amino acids in a single chain (Hadley and Levine, 2007). Due to
the similarity of the first 13 amino acids in ACTH and MSH, ACTH has considerable
melanotropic activity (Hadley and Levine, 2007). The major role of ACTH is stimulation of
steroid biosynthesis (corticosteroids) in the adrenal cortex. The two glucocorticoids that are
produced from the adrenal gland in response to ACTH are cortisol and corticosterone, which are
both important to carbohydrate metabolism (Hadley and Levine, 2007). Cortisol is the more
commonly produced corticosteroid in most mammals.
Adrenocorticotropic hormone, which is dependent upon the trophic hypothalamic peptide
corticotrophin releasing hormone (CRH; Hadley and Levine, 2007) for its production and
5

secretion, is further regulated by negative feedback control of the adrenal glucocorticoids.
Elevated cortisol concentrations, or exogenous treatment with the glucocorticoid analog,
dexamethasone, inhibit further ACTH secretion until the high concentrations abate. It is this
feedback loop that is the basis of the dexamethasone suppression test for Cushing's syndrome
(hyperadrenalism; Hadley and Levine, 2007).
Intracellular production of ACTH is via a large prohormone referred to as
proopiomelanocortin, or POMC (Hadley and Levine, 2007). This 241 amino acid peptide is
cleaved from a pre-prohormone (pre-proopiomelanocortin) that is 285 amino acids in length.
Within the corticotrope, ACTH is cleaved from POMC by proteases specific to the corticotrope
(Chrétien and Seidah, 1981). This latter specificity is important, because POMC contains within
its sequence the sequences of ACTH, β-lipotropin, α-MSH, β-MSH, γ-MSH, and β-endorphin
(Hadley and Levine, 2007).
Cushing's Syndrome
Cushing's syndrome is the complex series of changes that occur in animals due to
hypersecretion of adrenal glucocorticoids (Guyton and Hall, 2006). In humans, Cushing's
syndrome is often associated with hypothalamic or pituitary adenomas resulting in excessive
CRH or ACTH secretion, or alternatively, with ectopic secretion by adenomas in other parts of
the body, or by adenomas in the adrenal gland itself (Guyton and Hall, 2006). Hyperadrenalism
due to excessive ACTH secretion by the adenohypophysis is specifically referred to as Cushing's
disease (Guyton and Hall, 2006).
Diagnosis of the cause of Cushing's syndrome usually starts with measurement of both
plasma cortisol and ACTH concentrations. If cortisol concentrations are high, but ACTH
concentration is low or undetectable, it is likely that the normal feedback loop sites in the
hypothalamus and pituitary are intact and functioning normally. If both ACTH and
6

glucocorticoid concentrations are high, it is likely that the problem arises from the hypothalamus
or adenohypophysis, or perhaps from an ectopic source of ACTH. The dexamethasone
suppression test, mentioned above, is used to determine whether the normal glucocorticoid
feedback effect on the hypothalamic-adenohyphyseal axis is intact and functional. That is,
dexamethasone treatment in the evening is expected to cause a significant drop in corticosteroid
concentration in blood by the following morning in normal (non-Cushing's) horses.
Melanocyte Stimulating Hormone
Although three forms of MSH have been described (α, β, and γ), α-MSH is the
predominant form and is believed to be the biologically relevant form in most animals (Hadley
and Levine, 2007). Melanocyte stimulating hormone is produced and secreted by the pars
intermedia of the adenohypophysis, which lies between the pars distalis and pars nervosa in most
vertebrates (a distinct pars intermedia is notably absent in the humans and birds; Hadley and
Levine, 2007). Melanocyte stimulating hormone is comprised of 13 amino acids and plays an
important role in skin coloration for many vertebrates (Hadley and Levine, 2007). Like prolactin,
disruption of hypothalamic input to the pituitary increases, rather than decreases, MSH secretion
(Hadley and Levine, 2007), indicating a tonic inhibitory action by the hypothalamus. Dopamine
is now known to be the hypothalamic factor inhibiting MSH by interacting with the
dopaminergic receptors on the cell membranes of the pars intermedia cells. Release of dopamine
holds the cells in a hyperpolarized state and causes the inhibitory effect (Hadley and Levine,
2007).
Aside from aiding in skin or coat pigmentation, MSH has been known to have other
physiological roles. For example, a large dose of MSH given subcutaneously results in an
erection in men, aids in satiety and energy homeostasis and thermoregulation in some species,
induces positive behavioral effects (arousal, increased motivation, longer attention span, memory
7

retention, and increased learning ability), and neuroplasticity, causing alterations in
neurotransmitter synthesis, electrophysiological parameters of neurotransmission, excitability in
the spinal cord and peripheral nerves, and behavioral responses (Hadley and Levine, 2007).
Like ACTH in corticotropes, MSH in the melanotropes is derived from POMC. Proteases
specific to the melanotropes cleave POMC such that the predominant product is MSH, although
in mice, β-endorphin has also been shown to be produced (Saiardi and Borrelli, 1998). Treatment
with glucocorticoids or dexamethasone does not perturb the production of POMC or MSH by the
melanotropes (Hadley and Levine, 2007), whereas the absence of dopaminergic control (via D2
receptor gene knockout) in mice resulted in pars intermedia hypertrophy, excessive POMC
production, and ACTH secretion (Saiardi and Borrelli, 1998). This unusual ACTH production
likely indicates a change in the proteases produced in the cell as a result of the lack of
dopaminergic input.
Pituitary Pars Intermedia Dysfunction in Horses
Pituitary pars intermedia dysfunction is a slow progressing disorder with characteristic
clinical signs in horses 15 years and older (Messer, 1999; McFarlane, 2011). It has also been
referred to as equine Cushing’s disease, due to the similarities is has with human Cushing’s
syndrome. However, unlike the human disease, the cause of equine PPID is adenomas within, or
adenomatous hypertrophy of, the pars intermedia of the pituitary gland (Messer, 1999). Tumor
formation within the intermediate lobe causes an increase in production of POMC peptides, due
to an abnormal stimulation of the melanotropes. Often, there is a loss of function in the adjacent
tissues due to compression on the tissues by the swelling lobe (McFarlane et al., 2006). The
increase in POMC production also results in large amounts of MSH and β-endorphin-related
peptides, as well as a small amount of ACTH. Melanocyte stimulating hormone and the βendorphin-related peptides can result in a six-fold potentiation of ACTH activity; that, combined
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with the small increase of ACTH synthesis from POMC, is enough to stimulate adrenocortical
steroidogensis, resulting in an increase in plasma cortisol concentrations and the loss of the
diurnal cortisol secretion pattern (Messer, 1999). McFarlane et al. (2003), based on a review of
the available literature, suggested that PPID may result from dopaminergic neurodegeneration
due to oxidative stress. Oxidative stress leads to a modification in cellular components, such as
proteins, DNA, and cell membrane lipids, caused by excessive exposure to exogenous sources of
oxidants. The damage to the cells leads to cell death, or neurodegeneration for neurons; with the
loss of function of the dopaminergic neurons, dopamine inhibition on the pars intermedia is
reduced or lost (McFarlane et al., 2003).
Clinical signs of PPID can include hirsutism (excessive hair coat that fails to shed in the
spring and summer months), muscle atrophy, lethargy, bulging supraorbital fat pads, recurrent or
chronic laminitis, susceptibility to infections (e.g. recurring sole abscesses), polyuria and
polydipsia (excessive urination and thirst), and infertility (McFarlane et al., 2003; Donaldson et
al., 2004). Hirsutism and abnormal fat deposits are the most common symptoms of this disease.
The current treatment for equine PPID is pergolide, a dopaminergic agonist (Donaldson
et al., 2004). Melanotropes are kept under tonic suppression through the hypothalamic axis, via
D2 receptors on their cell surface, and are inhibited by dopamine. Due to dopaminergic
neurodegeneration in older animals, dopamine can no longer be produced or secreted to inhibit
production (McFarlane et al., 2003). Based on this model, Sojka et al. (2006) suggested that
pergolide would be the most effective treatment for PPID.
Rational for Present Experiments
The goal of the experiments presented herein was to determine whether the measurement
of prolactin, or perhaps its response to the dopamine antagonist, supliride, could be used in
horses as a model for potential efficacy tests on dopamine agonists, pergolide, and an alternative,
9

cabergoline for the treatment of PPID in horses. Because of the mutual regulation (tonic
inhibition) of MSH and prolactin by hypothalamic dopamine, secretion and changes in secretion
of the two hormones would be expected to occur in parallel. That is, doses and vehicle
formulations of pergolide and cabergoline that inhibit prolactin may at the same time indicate the
effect they would have on MSH. Because prolactin can be measured easily and cheaply, relative
to MSH, in the LSU School Animal Sciences laboratory, it is presently the desired route for such
assessments. Thus, the experiments described herein were specifically designed to 1) determine
the repeatability of prolactin responses to a low dose of sulpiride given over an extended period
of time in geldings, 2) to determine similarly the repeatability of responses of mares and any
effect of the estrous cycle, 3) to determine the relative inhibitory effect (degree and time span) of
pergolide and cabergoline formulations on resting prolactin concentrations in geldings, and 4) to
determine the relative inhibitory effect (degree and time span) of specific pergolide and
cabergoline formulations on the sulpiride-induced prolactin response in mares.
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CHAPTER 2
REPEATABILITY OF PROLACTIN RESPONSES TO A LOW DOSE
OF SULPIRIDE IN GELDINGS
Introduction
Prolactin secretion in horses is under tonic suppressive control by hypothalamic
dopamine secretion, and thus can be temporarily stimulated by an intravenous injection of a
dopamine receptor antagonist such as domperidone or sulpiride (Johnson and Becker, 1987;
Brendemuehl and Cross, 2000; Donadeu and Thompson, 2002). Given that melanotropes, the
cells that produce and secrete MSH in the intermediate lobe of the pituitary gland, are also under
tonic, suppressive control by hypothalamic dopamine secretion (Hadley and Levine, 2007), it is
possible that prolactin secretion in response to sulpiride may also reflect simultaneous MSH
secretion. If so, then monitoring prolactin secretion could be used in lieu of measuring MSH
concentrations in horses for the study of the efficacies and durations of activity of dopaminergic
drugs (e.g., pergolide).
For long-term studies, prolactin response to injections of sulpiride for such use would
require a relatively repeatable response from shot-to-shot, and even day-to-day, in the absence of
any competing drug. Because repeated injections of sulpiride at or above the known saturating
dose (about 50 mg of the +/- racemic mixture of sulpiride in a 500 kg horse) are known to result
in a rapid decreases in prolactin response in geldings in late winter (Thompson and DePew,
1997), it is likely that a lower dose, perhaps 20 to 40% of maximal, would be needed to avoid the
depletion of pituitary prolactin reserves. Moreover, to ensure easily measured plasma prolactin
concentrations in winter, when prolactin secretion is naturally low, pretreatment with estradiol,
which has been shown to enhance prolactin responses to sulpiride (Kelley et al., 2006;
Thompson et al., 2008), might be of benefit.
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The present experiment was designed to determine whether prolactin responses to a low
dose of sulpiride in estrogen-primed geldings would be consistent enough to provide a basis for
further development of a model for the future assessment of dopaminergic drugs in horses.
Materials and Methods
Six light horse, long-term geldings housed at the LSU Agricultural Center horse farm
were used. They were between 6 and 20 years old, weighed between 410 and 526 kg, and had
body condition scores between 5 and 8 (Henneke et al., 1983). They were routinely kept on
native grass pasture most of the year, and on winter ryegrass pasture when native grasses were
dormant. They remained on pasture except when experimental procedures were being performed.
On March 31, 2011, all geldings received a single intramuscular injection of 100 mg of
estradiol cypionate (ECP; Biorelease estradiol cypionate LA, 50 mg/mL; BetPharm Pharmacy,
www.betpharm.com) to stimulate prolactin. Sulpiride challenges were started on April 5, 2011,
and were continued every-other-day through April 19, 2011. For each day of treatment and blood
sampling, the geldings were brought in from pasture the evening before and were kept in a small
lot with native grass hay and water available for ad libitum consumption. At approximately
08:00 the morning of blood sampling, the geldings were tethered loosely either in an outdoor
chute or under an open–sided shed. A single sample of jugular blood was obtained via
venipuncture from each of the geldings, and then sulpiride was injected intravenously. The dose
of the +/- racemic mixture of sulpiride (Sigma Chem. Co., St. Louis, MO) was 5 µg/kg BW. The
sulpiride was dissolved in sterile saline with sufficient NaOH added to result in complete
solubilization; the final concentration of the solution was 0.5 mg/mL.
Samples of jugular blood were collected subsequently at 10, 20, 40, and 60 min after
sulpiride injection. All blood samples were collected through 22-guage needles into tubes
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containing 100 units of sodium heparin. The samples were placed at 5°C until centrifugation at
1200 x g for 15 min; plasma was harvested and was stored at -15°C.
The procedures described above were repeated on alternate days for a total of 8 sulpiride
challenges. When all plasma samples had been collected, prolactin concentration was measured
by radioimmunoassay (Colborn et al., 1991). From the raw prolactin data, two additional data
sets were derived: 1) net changes in prolactin concentration from time 0, and 2) net areas under
the response curve. The net change in concentration, which should be proportional to the amount
of prolactin released in the first few minutes after sulpiride injection, was the difference between
the highest prolactin concentration achieved after sulpiride injection (usually the 10 min sample)
minus the time 0 (pre-injection) concentration. The net areas under the response curve were
calculated by first subtracting the pre-injection concentration from all subsequent values, and
then summing the concentration x time increments (rectangle summation). The net differences
and the net areas were analyzed by ANOVA with SAS (SAS Instit., Cary, NC) with horse and
day as the main factors; the horse x day interaction served as the error term. Differences among
days were assessed by the least significant difference test (Steel et al., 1997). Linear and
quadratic trends in means for days were assessed by appropriate "contrast" statements in the SAS
program.
Results
All geldings responded to the low dose of sulpiride with robust increases in plasma
prolactin concentrations (Figure 2.1).
Analysis of the net changes in prolactin concentrations and the areas under the response
curves provided essentially the same information. Both dependent variables were affected (P <
0.001) by day of sulpiride challenge. Moreover, both variables showed a linear (P < 0.002)
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Figure 2.1. Plasma concentrations of prolactin in 6 geldings administered sulpiride at 5 µg/kg
BW on 8 alternate days beginning April 5, 2011. All geldings received a single injection of
estradiol cypionate on March 31, 2011.

and a quadratic (P < 0.003) component in the means of the 8 days of challenge (Figure 2.2), with
an upward trend in the first few days followed by a plateau.
The within-gelding coefficients of variation ranged from 16 to 41% for the net increase in
prolactin concentrations and from 20 to 35% for the net areas under the response curves.
Discussion
The prolactin responses to sulpiride in these geldings were relatively robust over the 8
challenges compared to geldings administered a saturating dose of sulpiride (100 mg of the +/-
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Figure 2.2. Mean net changes in prolactin concentrations and net areas under the response
curves for geldings administered sulpiride at 5 µg/kg BW on 8 alternate days beginning April 5,
2011. All geldings received a single injection of estradiol cypionate on March 31, 2011. There
were significant linear (P < 0.001) and quadratic (P < 0.002) components for both dependent
variables. The pooled SEM were 15.5 ng/mL and 5.9 ng•mL-1•h for net changes and areas,
respectively.

racemic mixture, or approximately 160 to 200 µg/kg BW) daily starting on February 8
(Thompson and DePew, 1997). In that experiment, the geldings were not pretreated with
estradiol, and the mean prolactin response (area under curve) decreased from 25 ng•mL-1•h in the
first week to 10 ng•mL-1•h in the second week of treatment, indicating a 60% depletion of
pituitary reserves of prolactin. Treatment of the geldings in the present experiment with estradiol
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stimulated prolactin to the extent that the average response to sulpiride at 5 µg/kg BW was
greater than the average response to the saturating dose in the geldings of Thompson et al.
(1997). Moreover, rather than decreasing from the first day to the last, the prolactin responses in
these estradiol-primed geldings increased gradually to a plateau. This stimulation of prolactin
secretion by the estradiol-sulpiride combination is in fact dependent upon both components
(estradiol and a dopamine antagonist) being present. The results of Kelley et al. (2006)
demonstrated how prolactin secretion in seasonally anovulatory mares is greatly stimulated by
the simultaneous treatment with estradiol and sulpiride, but how prolactin secretion begins to
decrease soon after estradiol treatment stops. Thus, the prolactin responses to the low dose
injections of sulpiride in the present experiment would likely have started diminishing in
magnitude over time if no further ECP injection was given, based on the plasma estradiol
patterns reported by Thompson et al. (2008) after a 100-mg injection of ECP to geldings in
November. In that experiment, mean plasma estradiol concentrations after ECP injection
increased to approximately 20 pg/mL in 3 days and returned to baseline at approximately 20
days.
Although a perfectly repeatable situation would be one in which the prolactin response
was unchanged over time and the variation among responses was close to zero, the results
obtained here do seem to have potential as a means to study the efficacy and duration of activity
of dopamine agonists. That is, successful dopaminergic agonist treatment would be one in which
the prolactin response to low-dose sulpiride injection was completely blocked (basically no
response). Even with the 20 to 35% intra-gelding coefficient of variations for net areas under the
response curves, the prolactin responses to sulpiride would still be easily differentiated from no
response, and would thus provide information as to the efficacy of a given dose of agonist and its
duration of action.
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Compared to daily, oral administration of pergolide, which is the current standard
treatment for PPID horses (Schott, 2002), formulations of pergolide or cabergoline in vehicles
that provide several days to perhaps weeks of drug release are possible. Biodegradable polymers
are commonly used to deliver drugs by intramuscular injection for slow release over time
(Jeonga et al., 1999). Polymer-based in-situ formings (solutions that form hydrophobic depots in
aqueous environment after injection) are another class of vehicle used for slow-release drug
delivery, of which sucrose acetate isobutyrate (SAIB) is a prime example. Both SAIB and
biodegradable microparticle vehicles have been successfully tested at the LSU Agricultural
Center horse farm (Storer et al., 2009) for the extended delivery of altrenogest, a progestogen
used in the horse industry for the synchronization of estrus and the long-term suppression of
estrus and ovulation in mares (Webel and Squires, 1982). The application of these technologies
to delivery systems for dopamine agonists for the treatment of PPID certainly deserves further
study.
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CHAPTER 3
REPEATABILITY OF PROLACTIN RESPONSES TO A LOW DOSE OF SULPIRIDE
IN MARES: EFFECT OF THE ESTROUS CYCLE
Introduction
It was shown in Chapter 2 that treating estrogen-primed geldings with low dose sulpiride
injections every other day resulted in relatively consistent prolactin responses. Like geldings,
mares can be kept in groups on pasture and may also serve as convenient test animals in
experiments testing the efficacy and duration of action of dopaminergic agonists such as
pergolide and cabergoline. Unlike geldings, mares have cyclic changes in their internal steroid
milieu during the breeding season, with elevated progesterone concentrations during diestrus and
elevated estrogen concentrations during estrus (Ginther, 1992). Although Johnson (1986)
reported that plasma prolactin concentrations did not vary across the estrous cycle in mares, there
is no information on the possible interaction of estrogen secretion during estrus and
administration of dopamine antagonists such as sulpiride or domperidone. Thus, the present
experiment was designed to determine whether low dose sulpiride injections administered every
other day to cyclic mares would result in similar plasma prolactin responses, similar to geldings,
or whether the changing steroidal conditions would alter the responses.
Materials and Methods
Six light horse mares with previous histories of displaying normal estrous cycles were
used. They ranged in age from 6 to 15 years, weighed between 498 and 556 kg, and had body
condition scores between 6 and 8 (Henneke et al., 1983). They were routinely housed on native
grass pastures at the LSU Agricultural Center horse farm. They remained on pasture except when
experimental procedures were being performed.
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Beginning on July 3, 2011, and continuing every other day thereafter through July 31,
2011, all mares received an intravenous injection of sulpiride in saline in the morning. For each
day of injection, the mares were brought in from pasture the evening before and were kept in a
small lot with native grass hay and water available for ad libitum consumption. At approximately
08:00 the morning of blood sampling, the mares were tethered loosely either in an outdoor chute
or under an open-sided shed. A single sample of jugular blood was obtained via venipuncture
from each of the mares, and then sulpiride was injected intravenously. The dose of the +/racemic mixture of sulpiride (Sigma Chem. Co., St. Louis, MO) was 5 µg/kg BW. The sulpiride
was dissolved in sterile saline with sufficient NaOH added to result in complete solubilization;
the final concentration of the solution was 0.5 mg/mL.
Blood was obtained via jugular venipuncture into heparinized, evacuated tubes
immediately before injection (time 0) and at 10, 20, 40, and 60 min after injection. Plasma was
harvested by centrifugation (1200 x g for 15 min) and was stored at -15°C. Prolactin was
measured in all plasma samples as described by Colborn et al. (1991). Although the mares were
not subjected to heat detection, the initial plasma sample on each day of sulpiride challenge was
used to measure LH concentration (Thompson et al., 1983) to help identify the stage of the
estrous cycle of each mare throughout the experimental period.
The raw prolactin data were used as described in Chapter 2 to calculate the net changes in
plasma prolactin concentrations and the net areas under the response curves for each sulpiride
challenge for each mare. These data were subjected to ANOVA in SAS (SAS Instit., Cary, NC)
with mare and day of challenge as main effects, and the interaction served as the error term.
Based on LH concentrations, the net changes and areas were further characterized as occurring in
1) the follicular phase, 2) early diestrus, or 3) late diestrus. The period of rising and highest LH
concentrations were considered to denote the follicular phase (Ginther, 1992); the period of
19

decreasing LH up to the next LH rise was considered the diestrous phase, which was further
divided approximately in half and denoted early and late diestrus. These data were analyzed by
ANOVA with mare, stage of the estrous cycle, and their interaction as factors; the replicated
challenges and their interaction with mare and stage of the cycle made up the error term.
Results
Like in geldings in Chapter 2, the prolactin responses to the low dose of sulpiride were
generally robust throughout the 30-day period in these mares (Figure 3.1). Analysis of the net
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Figure 3.1. Plasma concentrations of prolactin in 6 mares administered sulpiride at 5 µg/kg BW
on 15 alternate days beginning July 5, 2011. The days of peak LH concentrations are indicated
with an asterisk; mare 555 had low LH concentrations throughout the 30-day period.
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change in prolactin concentrations and the net areas under the response curves indicated no effect
(P > 0.1) of day of sulpiride challenge (Figure 3.2).
There were occasional low responses in some mares, however they were not associated
with any of the 3 estrous cycle categories, as evidenced by the lack of effect of estrous cycle
status (P > 0.1) for both net change in prolactin concentrations and net area under the response
curves (Figure 3.3).
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Figure 3.2. Mean net changes in prolactin concentrations and net areas under the response
curves for mares administered sulpiride at 5 µg/kg BW on 15 alternate days beginning July 5,
2011. There was no effect (P > 0.1) of day of sulpiride challenge for either variable. The pooled
SEM were 12.6 ng/mL and 7.2 ng•mL-1•h for net changes and areas, respectively.
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Intra-mare coefficients of variation ranged from 18 to 32% for net change in prolactin
concentrations, and from 18 to 30% for net areas under the prolactin response curves.
Discussion
The prolactin responses to this low dose of sulpiride in mares were similar to, but perhaps
slightly lower than, those observed in estrogen primed geldings in Chapter 2. The prolactin
responses would be expected to be greater in July than in April, due to the naturally occurring
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Figure 3.3. Mean net changes in prolactin concentrations and net areas under the prolactin
response curves in mares during the follicular phase (Fol.), early diestrus (Early di.), and late
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seasonal variations in plasma and pituitary prolactin concentrations (Johnson, 1986; Thompson
et al. 1986a). Also, these mares received no estrogen priming before the start of sulpiride
challenges. Apparently their own natural changes in plasma estradiol concentrations over the
estrous cycle was insufficient to stimulate prolactin secretion, given the lack of effect of estrous
cycle status on the net changes and net areas under the curves. This lack of estrous cycle stage
effect on the prolactin responses to sulpiride is similar to the lack of estrous cycle stage effect on
plasma prolactin concentrations reported originally by Johnson (1986).
Aurich et al. (1995) reported that both LH and prolactin were immediately released in
response to the opioid antagonist, naloxone, in ovariectomized pony mares pre-treated for 8 days
with estradiol or the combination of estradiol and progesterone. In contrast, there was no
response to naloxone in mares not receiving steroid treatment or in mares treated with only
progesterone. Whether the normally occurring changes in estrogen concentrations in mares over
the estrous cycle might be sufficient to result in a naloxone-induced prolactin response needs to
be determined.
Given that the prolactin response to low dose sulpiride challenge is generally repeatable
across the estrous cycle, mares then provide another possible model for the testing of
dopaminergic drugs for the possible treatment of PPID in horses. The occasional poor response
observed in these mares (e.g., the 12th response in mare 521 and the 13th response in mare 562)
stood out as exceptional but totally unexplained. One technical possibility would be failure to
inject the entire sulpiride dose into the jugular vein, however this should have been obvious to
the person doing the injecting. The poor responses occurred somewhat randomly and were not
associated with stage of the estrous cycle.
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CHAPTER 4
INHIBITORY EFFECTS OF PERGOLIDE AND CABERGOLINE ON PLASMA
PROLACTIN CONCENTRATIONS IN GELDINGS: DURATION OF EFFECT
Introduction
Pergolide is a dopamine receptor agonist that is used in some countries as a treatment for
Parkinson's disease. It was removed from the U.S. market in 2007 for human use due to an
association of its use with heart valve dysfunction (Rasmussen et al., 2011), however it remains
available for compounding by veterinary pharmacies to be sold as a treatment for PPID in horses
(starting at 0.5 to 1.0 mg/day orally and gradually increasing the daily dose to up to 6 mg/day).
Cabergoline is another dopamine receptor agonist that is highly active on D2 receptors
(Seeman, 2007). It was also commercially available for human use, and went off patent in 2005,
but has the same potential side-effects as pergolide (Rasmussen et al., 2011). It may be a
potential replacement for pergolide for use in horses due to its long acting nature (Godbout et al.,
2010).
The objective of the present experiment was to determine and compare the effects of the
current drug of choice, pergolide, in two possible formulations (oral administration and
intramuscular injection) to cabergoline (injected), on the unstimulated daily plasma prolactin
concentrations in geldings.
Materials and Methods
Sixteen light horse, long term geldings were used. They ranged in age between 6 and 20
years old, weighed between 410 and 616 kg, and had body condition scores between 5 and 8
(Henneke et al., 1983). All horses were located at the LSU Agricultural Center horse farm and
were maintained on native grass pasture.
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The 16 geldings were randomly assigned to one of the four treatment groups (n =
4/group): control, pergolide injection, cabergoline injection, and oral pergolide administration.
On August 20, 2011, all geldings were treated at 08:00 in the morning. All injections (treatments
and vehicle) were given intramuscularly and the pills (pergolide) were administered with the aid
of a pill gun; geldings not receiving oral treatment had the pill gun placed into their mouth to
equalize stress levels across treatments. The geldings were kept in a small pasture lot close to the
site of treatment and blood collection. On the morning of treatment, and for every blood
collection after treatment, horses were loosely tethered in an outdoor chute.
Blood samples were obtained via jugular venipuncture into heparinized, evacuated tubes
12 and 24 hours before treatment; immediately before injection (time 0 on day 0); at 1, 3, 6, 9,
and 12 hours after injection; and every 12 hours thereafter until the morning of day 6. Plasma
was harvested from all samples by centrifugation (1200 x g for 15 min) and was stored at -15°C.
Prolactin was measured in all plasma samples as described by Colborn et al. (1991).
Prolactin concentrations were analyzed in a one-way ANOVA with repeated measures
(sampling times) with treatment and time as main effects (SAS, SAS Instit., Cary, NC). The
treatment effect was tested with the animal-within-treatment term, and time and the interaction
were tested with residual error. The significance of differences between groups for each time
period was tested by the least significant difference test (Steel et al., 1997).
Results
Mean plasma prolactin concentrations in the four groups of geldings are shown in Figure
4.1. The means for each treated group are plotted against the means for the vehicle-treated
(control) geldings for clarity. There was an effect of treatment (P = 0.061) as well as a treatment
x time interaction (P = 0.0062) in the ANOVA. Relative to controls, all treatments reduced (P <
0.05) prolactin concentrations, but the treatments varied as to the degree of reduction and to the
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Figure 4.1. Mean plasma prolactin concentrations in the first 48 hours in vehicle-treated
geldings (control) and those receiving an injection of 5 mg of cabergoline (top panel), an
injection of 2 mg of pergolide (middle panel), or oral pergolide (2 mg; bottom panel). Pooled
SEM was 1.6 ng/mL for prolactin concentrations.

duration of reduction. Oral pergolide reduced prolactin concentrations only at 3 and 6 hours,
down to 2.7 ng/mL, after administration, whereas the injection of pergolide reduced prolactin
concentrations from 6 to 24 hours after treatment, down to 1.6 ng/mL. Cabergoline injection
reduced prolactin concentrations to <1 ng/mL for the first 2 days and to <1.6 ng/mL thereafter
through day 6 (Figure 4.2).
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geldings (control) and those receiving an injection of 5 mg of cabergoline (top panel), an
injection of 2 mg of pergolide (middle panel), or oral pergolide (2 mg; bottom panel). Only
cabergoline reduced prolactin concentrations during this period (*P < 0.05; †P < 0.1). Pooled
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Discussion
Although a starting dose of pergolide of 0.5 to 1.0 mg/day orally is recommended for
horses suspected of having PPID (Donaldson et al., 2004; Schott, 2002), a single dose of 2 mg
was used in the present experiment as a typical dose that would be given after a gradual ramp up
to effect. It is not uncommon for the dose to be ramped up to as high as 6 mg/day (Donaldson et
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al., 2004; McFarlane, 2011). This 2 mg dose, when administered orally, had a very short-lived
effect on plasma prolactin concentrations. If the inhibitory effect on melanotropes in the
intermediate lobe of the pituitary gland were similar in degree and duration as the effect on
prolactin secretion, it seems that this mode of administration of pergolide is an unnecessary
waste of drug. Intramuscular injection of an equal amount of pergolide produced a full 24 hours
of suppression, and thus would be a more efficient and efficacious approach for treating PPID.
Cabergoline was administered as an injection, and at the 5 mg/horse dose, because it, in
combination with the slow-release vehicle used, was expected to last considerably longer than
the pergolide injections. The cabergoline injections definitely produced the greatest suppression
of prolactin concentrations in these geldings, and the duration of action was much longer than the
pergolide injections. Prolactin concentrations were generally suppressed by cabergoline even at
5.5 days after injection. If this efficacy and duration of activity can be shown to be consistently
obtained with larger groups of horses, a 5 to 6 day injection regimen would be vastly superior to
daily feeding or injection of pergolide.
Throughout the experiment, the geldings were observed while blood samples were
collected for any adverse signs due to the dopaminergic agonist treatments. No adverse behaviors
were noted in the 6 day period of sample collection, nor were there any signs of irritation or
swelling at the site of injections. It was concluded that the pergolide and cabergoline
formulations for injection deserved further study as a potential treatment for PPID in horses.
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CHAPTER 5
INHIBITORY EFFECTS OF DAILY PERGOLIDE INJECTIONS VERSUS A SINGLE
INJECTION OF CABERGOLINE ON THE DAILY PROLACTIN RESPONSES TO A
LOW DOSE OF SULPIRIDE IN MARES
Introduction
The responses of unstimulated plasma prolactin concentrations in Chapter 4 indicated
that the injectable pergolide and cabergoline formulations in slow release vehicle had potential as
superior treatments for PPID in horses compared to daily oral dosing of pergolide. The ability of
these formulations to suppress the prolactin response to low dose sulpiride stimulation as
described in Chapters 2 and 3 was tested in mares.
Materials and Methods
Fifteen light horse mares were used. They ranged in age between 5 and 16 years old,
weighed between 480 and 616 kg, and had body condition scores between 5 and 8 (Henneke et
al., 1983). All horses were located at the LSU Agricultural Center horse farm and were
maintained on native grass pasture.
Mares were initially assigned to one of three groups of five based on their ages, body
weights, and body condition scores, such that the means for those characteristics in the three
groups were similar. The groups were then randomly assigned treatment: controls (saline
injected), daily pergolide injections, and a single injection of cabergoline. Control mares
received single intramuscular injections of saline daily from day 0 through day 6. The
cabergoline-injected mares received a single intramuscular injection of 5 mg of cabergoline in
slow-release vehicle on day 0 and then injections of saline from day 1 through day 6. The
pergolide-injected mares received single daily intramuscular injections of pergolide in slowrelease vehicle on days 0 through 6. All injections were given in the morning between 07:00 and
08:00.
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The low-dose sulpiride challenges (2 µg/kg BW of the +/- mixture in saline) were started
on day -2 (October 19, 2011), and were repeated on days -1, 0, 1, 2, 3, 4, 6, 8, and 10. The
sulpiride dose was reduced from 5 (Chapters 2 and 3) to 2 µg/kg BW because the prolactin
responses in those earlier experiments were more robust than needed for monitoring treatment
effects, and because the challenges in this experiment were to occur daily. The original
experimental protocol called for daily sulpiride challenges through day 10, however several
mares became averse to the injection and blood sampling regimen, and it was decided to go to an
every-other-day challenge after day 4. That change alleviated the behavioral problems.
For each sulpiride challenge, mares were prepared as described in Chapter 3. On day 0,
the day of first treatment injection, the sulpiride challenge was started 30 min after the treatment
injections. Blood was obtained via jugular venipuncture into heparinized, evacuated tubes at time
0 (treatment), 10, 20, 40, and 60 minutes relative to sulpiride injection. Plasma was harvested by
centrifugation (1200 x g for 15 min) and was stored at -15°C. Prolactin was measured in all
plasma samples as described by Colborn et al. (1991).
Plasma prolactin concentrations in response to sulpiride were analyzed in a one-way
ANOVA with two repeated measures (days and minutes within days). Also, areas under the
response curves were calculated for each mare on each day as described in Chapter 2; these areas
were analyzed in a one-way ANOVA with repeated measures (days). The significance of
differences between groups for each time period was tested by the least significant difference test
(Steel et al., 1997).
Results
Mean plasma prolactin concentrations in response to sulpiride challenges over the course
of the experiment are presented in Figure 5.1. There was an effect of treatment, day, and minute
of blood sampling (P < 0.01) as well as the three-way interaction (P < 0.001). Daily pergolide
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Figure 5.1. Mean plasma prolactin concentrations in response to low dose sulpiride challenges in
control mares and mares receiving daily injections of 2 mg pergolide (days 0 through 6) or a
single injection of 5 mg of cabergoline in slow-release vehicle on day 0. The sulpiride challenge
on day 0 was started 30 minutes after the treatment injections. The pooled SEM was 6.6 ng/mL.

injections and the single cabergoline injection both suppressed (P < 0.05) the prolactin response
to sulpiride through day 10. There was an effect of treatment even on day 0, just 30 minutes after
the first (or only) treatment injection, with cabergoline almost totally suppressing the prolactin
response to sulpiride challenge. When expressed as areas under the curves (Figure 5.2), the
responses after cabergoline were essentially zero after day 0, whereas there was a small response
in the pergolide-treated mares on day 0 and eventually on day 10 (which was 4 days after the last
pergolide injection).
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Figure 5.2. Mean areas under the prolactin response curves in control mares and mares receiving
daily injections of 2 mg pergolide (days 0 through 6) or a single injection of 5 mg of cabergoline
in slow-release vehicle on day 0. The sulpiride challenge on day 0 was started 30 minutes after
the treatment injections. The pooled SEM was 5.9 ng•mL-1•h.

Discussion
Daily oral pergolide administration is currently the treatment of choice for PPID in
horses. However, from the results of this study and those reported in Chapter 4, both oral and
injectable pergolide formulations have a relatively short duration of effectiveness of 24 hours or
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less. Injecting pergolide daily was effective in suppressing prolactin response to low dose
sulpiride challenge in the present experiment, whereas a single injection of 5 mg of cabergoline
was just as effective, and lasted for at least 10 days. The effects of the cabergoline injection may
last even longer, and the actual duration of effectiveness will have to be studied in future
experiments. Regardless, the high effectiveness and longer duration of activity of the cabergoline
formulation indicate that it is superior to pergolide in counteracting the antidopaminergic activity
of the injected sulpiride. Whether the results obtained herein for prolactin in response to sulpiride
will similarly apply to MSH and ACTH secretion in PPID mares needs to be determined in
future research.
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SUMMARY AND CONCLUSIONS
Four experiments were conducted in an effort to develop a method for assessing the
efficacy and duration of activity of dopaminergic agonists for the treatment of PPID in horses.
Prolactin secretion, which is under the same hypothalamic control (tonic dopaminergic
suppression) as MSH secretion, was used as a proxy for MSH secretion.
In the first experiment, it was determined that the prolactin response to a low dose of the
dopamine antagonist, sulpiride, was generally repeatable in estrogen-primed geldings in winter
over 8 every-other-day challenges. It was concluded that estrogen-primed, sulpiride-challenged
geldings in winter could serve as a model for the study of the efficacy and duration of activity of
potential dopaminergic drugs for the treatment of PPID in horses.
The second experiment was performed in the summer with mares previously displaying
estrous cycles, and again tested the repeatability of the prolactin responses to low dose sulpiride
injection administered every-other-day for 30 days. The responses in mares were generally
repeatable, as in geldings, and there was no effect due to stage of the estrous cycle (follicular
phase, early diestrus, and late diestrus). It was concluded that mares could serve as a model for
the study of potential dopaminergic drugs as well as geldings, and stage of the estrous cycle did
not have to be taken into account.
In the third experiment, two formulations of the dopamine agonist, pergolide, were tested
(2 mg administered orally and 2 mg injected in a slow-release vehicle) against a single
formulation of cabergoline (5 mg injected in a slow-release vehicle) and control injections
(vehicle) for their efficacy to reduce unstimulated plasma prolactin concentrations in geldings.
Oral pergolide reduced prolactin concentrations for only a few hours, whereas injected pergolide
suppressed prolactin concentrations for a full 24 hours. Injection of cabergoline suppressed
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prolactin concentrations for up to 5.5 days. It was concluded that the injectable formulations had
potential for further study as possible treatments for PPID in horses.
The last experiment tested the efficacy of daily pergolide injection (2 mg/day) versus a
single 5 mg injection of cabergoline, both in slow-release vehicle, for suppressing the prolactin
secretion induced by low dose sulpiride injections in mares. Daily injection of pergolide
suppressed the prolactin responses to sulpiride as long as the injections were given, plus another
2 to 3 days. The single cabergoline injection suppressed the prolactin responses to sulpiride for a
minimum of 10 days. Based on these results, cabergoline in slow-release vehicle seems to
provide an excellent possibility for administering dopaminergic activity to horses with PPID.
Whether these results are directly applicable to MSH and ACTH secretion in PPID horses needs
to be determined.
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